Healthcare [ 10/13 ] | Biotechnology [ 90/160 ]
NASDAQ | Common Stock
ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases.
Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure.
It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19.
The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial.
ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 1, 24 | -0.08 Increased by +6.13% | - |
| Oct 18, 23 | -0.1 Increased by +38.25% | - |
| Jul 21, 23 | -0.1 Increased by +53.32% | - |
| Apr 24, 23 | -0.09 Increased by +83.64% | - |
| Feb 24, 23 | -0.08 Increased by +85.45% | - |
| Oct 28, 22 | -0.16 Increased by +51.52% | - |
| Aug 2, 22 | -0.22 Increased by +35.29% | - |
| May 2, 22 | -0.55 Decreased by -66.67% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 0 Decreased by N/A% | -1.09 M Decreased by -36.13% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0 Decreased by N/A% | -1.42 M Increased by +32.64% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0 Decreased by N/A% | -958 K Increased by +68.85% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0 Decreased by N/A% | -896 K Increased by +72.57% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0 Decreased by N/A% | -800 K Increased by +85.91% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0 Decreased by N/A% | -2.11 M Increased by +55.14% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0 Decreased by N/A% | -3.08 M Increased by +36.39% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0 Decreased by N/A% | -3.27 M Increased by +20.32% | Decreased by N/A% Decreased by N/A% |